Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for Advanced Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients
NCT03792542Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in soft tissue sarcoma (STS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03792542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792542.